The article substantiates various theoretical and applied principles of developing high-tech pharmaceutical industries (HTPI). It is established that the key problem of developing countries in this area is the dependence on resources and markets of developed countries, while the involvement of advanced foreign technologies can be a catalyst for increasing the technological potential of host countries (subject to the availability of proper knowledge and human capital, changes in the institutional environment, and improved the framework conditions for innovation). In the context of the development of HTPI, the author shows the importance of the network nature of the acquisition by pharmaceutical companies of sustainable competitive advantages based on resources that are difficult to simulate or replace. It is substantiated that networks built with local research institutions, higher education institutions, and research units of other companies, give pharmaceutical manufacturers the opportunity to access complementary assets and become their specific resource, which provides unique competitive advantages.
The author reveals various methodological and statistical features of the categorization of industries by the level of technology in the conditions of globalization. It is substantiated that the current low value of the ratio of research and development (R&D) to value-added generated by pharmaceuticals of individual countries is not a sign of the industry’s low technological level, as the current revenues are the result of long-term R&D and harmonization procedures for launching new drugs with lags of 10-15 years.
A new tool for the study of international trade in high-tech pharmaceuticals is proposed, whose peculiar feature consists in the categorization of nomenclature items by end use; the List of high-tech medical and pharmaceutical intermediate goods is formulated (in accordance with SITC Rev.4 and UKT FEA); the following indicators are proposed: the coefficient of import dependence of pharmaceutical production, the coefficient of "purified" exports of pharmaceutical products and the coefficient of imports coverage with HTPI output, and the formulas for their calculation are provided. The author's approach is the first to create the opportunity to assess the scale of costs and the dependence of the pharmaceutical industry on imported components that embody advanced technologies and are the industrial supplies for HTPI.
It was found that in Ukraine the share of foreign intermediate high-tech goods in the consumption of the industry reaches 82.2%; the industry, working on imported substances, produces mainly products for the domestic market, without earning foreign currency, even to cover the cost of purchasing the necessary ingredients; manufacturers do not rely on synthesized chemical products of domestic production, primarily due to the fact that the products of the chemical industry for the needs of pharmaceuticals in Ukraine are virtually non-existent; and the increase in output depends on foreign technologies and intermediate goods. It is substantiated that Ukraine’s pharmaceutical industry is critically dependent on imported supplies to ensure the smooth operation of enterprises and the healthcare industry.
Key endogenous barriers that hinder the development of HTPI have been identified, including problems in the training of specialists and a lack of scientists whose competencies would contribute to solving the problems of endogenous development of the industry; lack of state aid to business entities for research, and technological and innovative activities; lack of own funds to increase expenditures on R&D and implementation of large-scale investment and innovation projects; and lack of cheap loans, due to which Ukrainian pharmaceutical manufacturers find themselves in unequal conditions compared to foreign competitors.
Conceptual bases of HTPI development in Ukraine are proposed; justified the expediency of legal changes, definition of strategic priorities and introduction of measures of development of HTPI in Ukraine based on the comprehensive approach, which will cover creation and development of pharmaceutical ingredients for medicines (chemical and biotechnological goods), medical products, fillers, packing materials, machinery and equipment for pharmaceuticals to help reduce the dependence on foreign technologies, and to increase the level of production localization, employment and revenues to the budgets of all levels.
Keywords:high-tech production, pharmaceuticals, industry, technologies, innovations, endogenous innovations, technological dependence, state policy
1. Salikhova, O.B., and Honcharenko, D.O. (2020). Endogenization of Economic Development through the Development of High-Tech Pharmaceutical Industries: Europe's Experience, Lessons for Ukraine. Biznes Inform – Business Inform, 2, 49-56.
doi.org/10.32983/2222-4459-2020-2-49-56 [in Ukrainian].
2. A New Industrial Strategy for Europe. Brussels, 10.3.2020 COM(2020) 102 final. Retrieved from
ec.europa.eu/info/sites/info/files/ communicationeu-industrial-strategy-march-2020_en.pdf [in English].
3. Pharmaceuticals – safe and affordable medicines (new EU strategy). Retrieved from
ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordablemedicines
4. Covid-19 exposes EU’s reliance on drug imports. Retrieved from
www.ft.com/content/c30eb13a-f49e-4d42-b2a8-1c6f70bb4d55
5. Heуets, V.M. (2018). Endogenization of the Economy Development in the Aspect of Equality of Rights Relations among the State, Business and Voting Subjects. Ekonomika Ukrainy – Economy of Ukraine, 7, 3-19.
doi.org/10.15407/economyukr.2018.07.003 [in Ukrainian].
6. Vishnevskiy, V.P. et al. (2013). Industrial Policy and Management of Industrial Development in the Context of Systemic Imbalances: Conceptual Foundations. Donetsk [in Russian].
7. Kindzerskyi, Yu.V. (2016). Anti-crisis industrial policy: variant of the domestic concept. Visnyk Natsionalnoi akademii nauk Ukrainy – Bulletin of the National Academy of Sciences of Ukraine, 10, 27-42.
doi.org/10.15407/visn2016.10.027 [in Ukrainian].
8. Dorovskyi, O.V. (2015). Justification of the Choice of Strategy for the Development of the Pharmaceutical Industry of Ukraine: avtoref. dys ... d-ra ekon. nauk : 08.00.03. Kharkiv [in Ukrainian].
9. Kostiuk, H., and Marhitych, V. On the National Drug Supply Strategy in Ukraine. Dzerkalo tyzhnia – Mirror of week. January 20, 2017. Retrieved from
zn.ua/ukr/promyshliennost/ pro-nacionalnu-strategiyu-zabezpechennya-likami-vukrayini-_.html
10. Discussion of the Draft Strategy for the Development of the Pharmaceutical Industry of Ukraine for 2010-2020 (May 18, 2010). Retrieved from
oormmpu.at.ua/news/obgovorennja_proektu_strategiji_rozvitku_farmacevtichnoji_promislovosti_ukrajini_na_2010_2020_roki/2010- 05-18-124
11. Deineko L.V. (Ed.). (2018). Development of Industry to Ensure the Growth and Renewal of the Ukrainian Economy. Institute for Economics and Forecasting of the NAS of Ukraine, Kyiv [in Ukrainian].
12. Salikhova, O.B., and Honcharenko, D.O. (2020). Politics of development of pharmaceutical industry inGermany: Lessons for Ukraine. Ekonomika Ukrainy – Economy of Ukraine, 10, 63-86.
doi.org/10.15407/economyukr.2020.10.063 [in Ukrainian].
13. Salikhova, O.B., and Honcharenko, D.O. (2020). The Pharmaceutical Industry of France. Zovnishnia torhivlia: ekonomika, finansy, pravo – Foreign trade: economy, finances, right, 2, 67-84.
doi.org/10.31617/zt.knute.2020(109)05 [in Ukrainian].
14. On approval of the State program of economic stimulation to overcome the negative consequences caused by restrictive measures to prevent the occurrence and spread of acute respiratory disease COVID-19 caused by coronavirus SARS-CoV-2, for 2020-2022. Retrieved from
www.kmu.gov.ua/npas/pro-zatverdzhennya-derzhavnoyi-programi-stimulyuvannya-ekonomiki-534-270520 [in Ukrainian].
15. Gerschenkron, A. (1962). Economic Backwardness in Historical Perspective. Cambridge: The Belknap Press of Harvard University.
16. Salikhova, O.B., and Honcharenko, D.O. (2020). Policy of Endogenous Development of Pharmaceuticals in China: Lessons for Ukraine. Ekon. prognozuvannâ – Economy and forecasting, 2, 139-157.
doi.org/10.15407/eip2020.02.139 [in Ukrainian].
17. Veblen, T. Imperial Germany and Th e Industrial Revolution. Retrieved from
core.ac.uk/download/pdf/7048899.pdf
18. Honcharenko, D.O. (2020). New Approaches to the Assessment of Foreign Trade in High-Tech Pharmaceuticals. Statystyka Ukrainy – Statistics of Ukraine, 1, 35-41.
doi.org/10.31767/ su.1(88)2020.01.04
19. Salikhova, O., and Bak, G. (2015). Concepts of the influence of technology transfer by transnational corporations on the economy of a recipient country. Ìstor. nar. gospod. ekon. dumki Ukr. – History of economics and economic thought of Ukraine, 48, 270-295 [in Ukrainian].
20. Heуets, V.M. (2014). Institutional conditionality of innovative processes in ukraine’s industrial development. Ekonomika Ukrainy – Economy of Ukraine, 12, 4-19 [in Ukrainian].
21. Salikhova, O.B., and Honcharenko, D.O. (2020). Pharmaceutical industry of Mexico: a lesson for Ukraine. Zovnishnia torhivlia: ekonomika, finansy, pravo – Foreign trade: economy, finances, right, 7, 47-69 [in Ukrainian].
22. Crafts, N.F.R. (1995, Dec.). Exogenous or Endogenous Growth? The Industrial Revolution Reconsidered. The Journal of Economic History, 55: 4, 745-772.
doi.org/10.1017/S0022050700042145
23. Simurina, J., Tolic, I. (2008, January). Dynamics of the technology progress in economic development . Ekonomska Istraživanja/ Economic Research, 21(3), 12-24.
24. Mayer, J. (1996, December). Implications of new trade and endogenous growth theories for diversification policies of commodity-dependent countries, 122. UNCTAD/OSG/DP/122. Retrieved from
core.ac.uk/download/pdf/7043238.pdf
25. Romer, Paul M. (1990, Oct.). Endogenous Technological Change. Journal of Political Economy, 98: 5, p. 71-102. Retrieved from
web.stanford.edu/~klenow/Romer_1990.pdf; doi.org/10.1086/261725
26. Romer, Paul M. (1987, May). Growth Based on Increasing Returns Due to Specialization. The American Economic Review, 77: 2, 56-62. Retrieved from
eclass.uoa.gr/modules/document/file.php/ECON206/Course%20material/Romer%20Growth%20Increasing%20Returns%20AER%201987.pdf
27. Grossman, Gene M., Helpman, E. (2018, January). Growth, trade and inequality. Econometrica, 86: 1, 37-83. Retrieved from
www.princeton.edu/~grossman/GrowthTradeInequality.pdf;
doi.org/10.3982/ECTA14518
28. Salikhova, O.B., Honcharenko, D.O. (2020). The Conceptual Foundations of the Strategy of Development of the High-Tech Industry of Pharmaceuticals and Medical Products in Ukraine till 2030. Biznes Inform – Business Inform, 7, 28-35. Retrieved from
doi.org/10.32983/2222-4459-2020-7-28-35 [in Ukrainian].
29. Frascati, M. (2002). Proposed Standard Practice for Surveys on Research and Experimental Development. Paris: OECD.
30. Salikhova, O. (2012). High-tech Industries: From Evaluation Methodology to Rise in Ukraine. Institute for Economics and Forecasting, NAS of Ukraine. Kyiv [in Ukrainian].
31. Annual detailed enterprise statistics for industry (NACE Rev. 2, B-E). European Commission. Retrieved from
ec.europa.eu/
32. Business expenditure on R&D (BERD) by NACE Rev. 2 activity. Retrieved from
ec.europa.eu/
33. Corporation tax in the Republic of Ireland. Retrieved from
en.wikipedia.org/wiki/Corporation_tax_in_the_Republic_of_Ireland
34. Why Ireland Is Attracting The World’s Top Pharmaceutical Companies and How You Can Benefit. Retrieved from
www.innopharmaeducation.com/news/why-ireland-attracting-the-worlds-top-pharmaceutical-companies-and-how-you-can-benefit
35. The Pharmaceutical Industry in Figures. Key Data 2020 (2020). Brussels: EFPIA. Retrieved from
www.efpia.eu/media/554521/efpia_pharmafigures_2020_web.pdf
36. Evaluate Pharma® World Preview 2020, Outlook to 2026. Retrieved from
info.evaluategroup.com/
37. Scientific and innovative activity of Ukraine in 2018. Retrieved from
www.ukrstat.gov.ua/
38. Scientific and innovative activity of Ukraine in 2019. Retrieved from
www.ukrstat.gov.ua/
39. Strategy for the development of medical education in Ukraine 27.02.2019. Retrieved from
moz.gov.ua/uploads/1/8475-medical_education_analytics.pdf
40. National accounts of Ukraine for 2018. Retrieved from
www.ukrstat.gov.ua/
41. Salikhova, O. (2011). High-tech capital goods in import structure of Ukraine. Economist – Economist, 9, 28-32. Retrieved from
nbuv.gov.ua/UJRN/econ_2011_9_7
42. Salikhova, O. (2012). High Tech lmports to Ukraine and its Critical Determinants. Nauka ta naukoznavstvo – Science and science knowledge, 4, 40-56. Retrieved from
dspace.nbuv.gov.ua/bitstream/handle/123456789/85921/05-Salikhova.pdf?sequence=1
43. UN Comtrade Database (2020). comtrade.un.org. Retrieved from
comtrade.un.org/data/ [Appeal data: March 1. 2020].
44. Statistical Yearbook for 2018. Retrieved from
www.ukrstat.gov.ua/druk/publicat/kat_u/2019/zb/11/zb_yearbook_2018.pdf
45. Science and Engineering Indicators 2020. Retrieved from
nsf.gov/statistics/seind/
46. Global life sciences outlook. Focus and transform. Accelerating change in life sciences (2019). Retrieved from
www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2019.pdf